Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STSA-1301 in Healthy Subjects and Patients With Immune Thrombocytopenia (ITP)
NCT06929299Phase 2Recruiting
- Sponsor
- Jiangsu BioJeTay Biotechnology
- Start
- May 2025
- Primary completion
- Sep 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of STSA-1301 in immune thrombocytopenia (ITP), sponsored by Jiangsu BioJeTay Biotechnology. Started May 2025; status: recruiting.
02
Drugs
STSA-1301
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT06929299.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06929299.